Oncology
Ameloblastoma
3
Pipeline Programs↗
2
Active Trials↗
1
Companies Involved↗
Ameloblastoma is an early-stage landscape with 3 programs across 1 company. The most active players are Novartis. 1 program is in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical1
Phase 1
No programs
Phase 21
Phase 31
Approved
No programs
Analysis
Trial Status
4
clinical trials
Completed1 · 25%
Recruiting1 · 25%
Not yet recruiting1 · 25%
Unknown status1 · 25%
Clinical Trials
Trial Activity
Clinical Study of Neoadjuvant Targeted Therapy for Ameloblastoma
Recruiting·SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University·Phase 2·NCT06653517·12 enrolled
Neoadjuvant Therapy With Conservative Surgery vs. Up-front Conservative Surgery for BRAF V600E-Mutated Ameloblastoma
Not yet recruiting·SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University·Phase 2/3·NCT06819605·46 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)